← All stocks

Corvus Pharmaceuticals, Inc.

CRVS Balanced
CIK 0001626971 #2415 in the set updated 18 Sep 2026
Bought (120 mo)
$48.97M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$62.61M
$0.00 on a plan · $9.78M straight out of an exercise
Sold at will
$52.82M
9 of 11 sales
Net
−$13.64M
−$3.86M against sales at will

By person

13 insiders · 101 transactions

There is no salary here to measure against. Corvus Pharmaceuticals, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
EcoR1 Capital, LLC entity
10% owner
$25.06M (2)
−$25.06M
81,077
0.0964%
$934.95K
−98.4%
ADAMS STREET PARTNERS LLC entity
10% owner
$5.00M (5)
+$5.00M
3,402,422
4.04%
$39.24M
+20.9%
Gould Terry P
Director
$5.00M (5)
+$5.00M
3,402,422
4.04%
$39.24M
+20.9%
Novo Holdings A/S entity
10% owner
$10.22M (2)
$14.25M (5)
−$4.03M
1,389,498
1.65%
$16.02M
−56.9%
MILLER RICHARD A MD
President and CEO
$3.24M (40)
+$3.24M
3,620,257
4.30%
$41.75M
+59.8%
ORBIMED ADVISORS LLC entity
Director
$12.44M (6)
$11.65M (2)
+$795.16K
15,218,304
18.09%
$175.49M
+13.3%
Thompson Peter A.
Director
$12.44M (6)
$11.65M (2)
+$795.16K
15,428,304
18.34%
$177.91M
+14.9%
LEA LEIV
Chief Financial Officer
$294.07K (7)
+$294.07K
332,644
0.3954%
$3.84M
+66.8%
Moore David Scott
Director
$250.24K (1)
+$250.24K
21,700
0.0258%
$250.24K
Jones William Benton
See Remarks
$50.42K (2)
+$50.42K
173,130
0.2058%
$2.00M
+52.2%
Grais Linda
Director
$24.50K (1)
+$24.50K
10,000
0.0119%
$115.32K
Buggy Joseph J
EVP, Discovery Research
351,186
0.4175%
$4.05M
0.0%
Verner Erik J.
VP, Chemistry Research
63,773
0.0758%
$735.40K
0.0%
Insider
Date
Role
Action
Shares
Price
Amount
Thompson Peter A.
27 Jun 2025
Director
Sold after exercise indirect
1,176,332
$4.16
$4.89M
ORBIMED ADVISORS LLC
27 Jun 2025
Director
Sold after exercise indirect
1,176,332
$4.16
$4.89M

What was left out

Form 4 filings counted 194
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 7
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 2
Sales at will 9
Transactions with no price 0
Shares from compensation/vesting 3,905,814
Sales filed before the plan box existed 9
History held since 8 Dec 2016